Emendo Bio
Emendo Biotherapeutics is a pioneering, next-generation CRISPR company. Our unique approach allows us to make any gene targetable, transforming the current landscape of genetic medicine. Founded and managed by a core group of graduates from the Weizmann Institute of Science, Emendo’s scientific team combines expertise in protein engineering, molecular biology, and gene editing systems. Our technology enables us to perform precision gene editing while maintaining high efficiencies, allowing us to address disorders and diseases that were previously considered untreatable.
